On Monday after a large scale US study, the Novavax vaccine maker said that the Novavax’s COVID-19 jab is more than 90 per cent effective, including against the other new variants of the virus.
In a statement the company has said that the jab demonstrated 100 per cent protection against moderate and severe disease, 90.4 per cent over all. The study had enrolled 29,960 participants across 119 sites in US and Mexico to evaluate the efficacy, safety and immunogenicity.
The headquarters of the company are in Maryland, and they said that it has intended to apply for regulatory approval by the third quarter of 2021. After the approval, the company will be on the course to make around 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year 2021.
Novavax’s President and Chief Executive, Stanley C. Erck said that the vaccine is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Novavax continues to work with a sense of urgency to complete their regulatory submission and to deliver the vaccine to the world that is still in great need of it.
Concerns remain for the many poor countries which have been left out of the global inoculation drive. In terms of the doses administered so far, the imbalance between the G7 and the low income countries have been defined by the World Bank as 73 to 1. Unlike the other rival jabs, NVX-CoV2373 (Novavax’s vaccine) does not have to be stored at ultra low temperatures.
It could be stored and stable at 2 to 3 degree Celsius, allowing the use of existing vaccine supply chain channels for the distribution of the said vaccine. This could optimistically mean that the shots should be more easy to be transported and administered in countries with far less developed health infrastructures.